Equities

Agios Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Agios Pharmaceuticals Inc

Actions
  • Price (EUR)22.40
  • Today's Change0.000 / 0.00%
  • Shares traded100.00
  • 1 Year change-31.71%
  • Beta0.9158
Data delayed at least 15 minutes, as of Feb 09 2026 07:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Key statistics

On Monday, Agios Pharmaceuticals Inc (8AP:FRA) closed at 22.40, 13.71% above the 52 week low of 19.70 set on Nov 20, 2025.
52-week range
Today
19.70Nov 20 202538.80Nov 19 2025
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open22.40
High22.40
Low22.40
Bid--
Offer--
Previous close22.40
Average volume246.40
Shares outstanding58.31m
Free float57.30m
P/E (TTM)--
Market cap1.55bn USD
EPS (TTM)-6.96
USD
Data delayed at least 15 minutes, as of Feb 09 2026 07:08 GMT.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.